Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 index. Investor excitement about news of a fresh product launch the previous ...

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that left investors unimpressed.

Investor excitement about news of a fresh product launch ... Zepbound. It's also gearing up to sell biosimilars of Novo Nordisk diabetes treatment liraglutide. Investors plowed into Hims & Hers ...

Hims & Hers is a newfangled telehealth company that ... Then, on 5/20/24, HIMS metaphorically pushed harder on the launch button. It announced it would make GLP-1 injections available to its ...

Shares of Hims & Hers Health (HIMS) rallied on Tuesday after ... This drug is sold as Mounjaro for Type 2 diabetes and Zepbound for obesity and has helped make Eli Lilly the most valuable drug ...

Eli Lilly's drive to provide as many treatment options as possible for its weight-loss drug Zepbound has continued ... Companies like Hims & Hers and WeightWatchers have been providing compounded ...

Teladoc stock has declined significantly, from a high of $14 per share in February to $7 per share. Read why I downgrade TDOC ...

It’s less “we got Zepbound” and more “look what you could be saving on.” The real news — and it got completely overshadowed — was the official launch of Hims & Hers’ $299/month generic liraglutide, a ...

Trial data data showed Lilly's experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer ...

On Tuesday, up-and-coming telehealth specialist Hims & Hers Health announced it aims ... This is the key ingredient in Eli Lilly's highly popular Zepbound obesity drug. As weight-loss drugs ...